Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR.

J Clin Oncol. 2013 Apr 10;31(11):1428-34. doi: 10.1200/JCO.2012.46.4396. Epub 2013 Mar 4.

PMID:
23460710
[PubMed - indexed for MEDLINE]
Free Article
2.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

PMID:
19509351
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort.

Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ.

Eur Urol. 2014 Jul 2. pii: S0302-2838(14)00521-1. doi: 10.1016/j.eururo.2014.05.039. [Epub ahead of print]

PMID:
24998118
[PubMed - as supplied by publisher]
4.

Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.

May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.

J Urol. 2007 Nov;178(5):1957-62; discussion 1962. Epub 2007 Sep 17.

PMID:
17868719
[PubMed - indexed for MEDLINE]
5.

External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients.

Yoshida T, Nakayama M, Takeda K, Arai Y, Kakimoto K, Nishimura K.

Urol Int. 2012;89(1):45-51. doi: 10.1159/000336924. Epub 2012 Mar 21.

PMID:
22441013
[PubMed - indexed for MEDLINE]
6.

Prognostic value of a cell cycle progression score for men with prostate cancer.

Cuzick J.

Recent Results Cancer Res. 2014;202:133-40. doi: 10.1007/978-3-642-45195-9_16.

PMID:
24531787
[PubMed - indexed for MEDLINE]
7.

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):848-53. doi: 10.1016/j.ijrobp.2013.04.043. Epub 2013 Jun 5.

PMID:
23755923
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.

Arsov C, Jankowiak F, Hiester A, Rabenalt R, Quentin M, Schimmöller L, Blondin D, Antoch G, Albers P.

Anticancer Res. 2014 May;34(5):2459-66.

PMID:
24778061
[PubMed - indexed for MEDLINE]
9.

Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.

Tamblyn DJ, Chopra S, Yu C, Kattan MW, Pinnock C, Kopsaftis T.

BJU Int. 2011 Nov;108 Suppl 2:51-6. doi: 10.1111/j.1464-410X.2011.10687.x.

PMID:
22085129
[PubMed - indexed for MEDLINE]
10.

External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series.

Loeb S, Carvalhal GF, Kan D, Desai A, Catalona WJ.

Urol Oncol. 2012 Sep;30(5):584-9. doi: 10.1016/j.urolonc.2010.06.007. Epub 2010 Sep 6.

PMID:
20822930
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.

Cooperberg MR, Hilton JF, Carroll PR.

Cancer. 2011 Nov 15;117(22):5039-46. doi: 10.1002/cncr.26169. Epub 2011 Jun 3.

PMID:
21647869
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.

Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW.

Urology. 2008 Aug;72(2):396-400. doi: 10.1016/j.urology.2007.11.165. Epub 2008 Apr 18.

PMID:
18372031
[PubMed - indexed for MEDLINE]
13.

Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy.

Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR.

Cancer. 2006 Nov 15;107(10):2384-91.

PMID:
17039503
[PubMed - indexed for MEDLINE]
Free Article
14.

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake DD 2nd, Wagner S, Gutin A, Lanchbury JS, Stone S; Transatlantic Prostate Group.

Lancet Oncol. 2011 Mar;12(3):245-55. doi: 10.1016/S1470-2045(10)70295-3.

PMID:
21310658
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

PMID:
20883488
[PubMed - indexed for MEDLINE]
16.

Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.

Budäus L, Isbarn H, Tennstedt P, Salomon G, Schlomm T, Steuber T, Haese A, Chun F, Fisch M, Michl U, Heinzer H, Huland H, Graefen M.

BJU Int. 2012 Dec;110(11):1714-20. doi: 10.1111/j.1464-410X.2012.11147.x. Epub 2012 Apr 23.

PMID:
22520619
[PubMed - indexed for MEDLINE]
17.

External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.

Ishizaki F, Hoque MA, Nishiyama T, Kawasaki T, Kasahara T, Hara N, Takizawa I, Saito T, Kitamura Y, Akazawa K, Takahashi K.

Jpn J Clin Oncol. 2011 Nov;41(11):1259-64. doi: 10.1093/jjco/hyr136. Epub 2011 Sep 22.

PMID:
21940731
[PubMed - indexed for MEDLINE]
Free Article
18.

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S; Transatlantic Prostate Group.

Br J Cancer. 2012 Mar 13;106(6):1095-9. doi: 10.1038/bjc.2012.39. Epub 2012 Feb 23.

PMID:
22361632
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G, Castaños-Vélez E.

J Urol. 2010 Jul;184(1):149-56. doi: 10.1016/j.juro.2010.03.012. Epub 2010 May 15.

PMID:
20478579
[PubMed - indexed for MEDLINE]
20.

Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.

Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR.

J Urol. 2005 Apr;173(4):1126-31.

PMID:
15758720
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk